◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › PFE

Pfizer Inc (PFE) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Pharmaceuticals · DATA UPDATED 2026-07-12

Pfizer Inc (PFE) operates in the Pharmaceuticals industry and is headquartered in New York, United States with about 75,000 employees. Its market capitalization is roughly $140 billion. In the fiscal year ended 2025-12-31, PFE reported $62.6B in revenue and $7.8B in net income.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.

Interactive charts & full statements → Open the PFE valuation workbench →

PFE Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$63.3B	$62.6B	$63.6B	$59.6B	$100.3B	$81.3B	$41.7B	$41.2B	$53.6B	$52.5B	$52.8B	$48.9B	$49.6B	$51.6B	$54.7B	$61.0B	$67.1B	$50.0B	$48.3B	$48.4B	$48.4B
Gross Profit	$43.9B	$44.0B	$41.8B	$30.3B	$62.1B	$46.9B	$29.9B	$28.5B	$37.6B	$36.8B	$36.9B	$35.7B	$36.3B	$37.6B	$40.0B	$43.9B	$46.3B	$38.4B	$38.3B	$36.7B	$37.9B
Gross Margin %	69.3%	70.3%	65.8%	50.9%	61.9%	57.7%	71.7%	69.3%	70.2%	70.0%	69.8%	73.1%	73.2%	73.0%	73.2%	71.9%	69.1%	76.8%	79.2%	75.8%	78.3%
Operating Income (EBIT)	$14.8B	$15.4B	$16.5B	$5.3B	$37.5B	$20.8B	$9.1B	$7.5B	$15.3B	$14.4B	$14.3B	$13.3B	$14.0B	$16.9B	$18.0B	$18.4B	$17.7B	$16.0B	$16.6B	$13.9B	$15.1B
Operating Margin %	23.4%	24.7%	25.9%	8.9%	37.4%	25.6%	21.8%	18.2%	28.5%	27.4%	27.0%	27.2%	28.3%	32.7%	33.0%	30.1%	26.4%	32.0%	34.4%	28.7%	31.2%
Net Income	$7.5B	$7.8B	$8.0B	$2.1B	$31.4B	$22.1B	$9.2B	$16.3B	$11.2B	$21.3B	$7.2B	$7.0B	$9.1B	$11.6B	$9.8B	$8.7B	$8.3B	$8.6B	$8.0B	$8.2B	$11.0B
Net Margin %	11.8%	12.4%	12.6%	3.6%	31.3%	27.3%	22.0%	39.5%	20.8%	40.6%	13.7%	14.3%	18.3%	22.6%	17.9%	14.3%	12.3%	17.3%	16.6%	17.0%	22.8%
EBITDA	$16.7B	$15.1B	$18.1B	$9.6B	$41.0B	$30.8B	$13.2B	$18.9B	$19.6B	$19.8B	$15.3B	$15.3B	$19.1B	$23.5B	$20.4B	$22.2B	$19.6B	$16.8B	$15.3B	$14.9B	$18.8B
Earnings Per Share (EPS)	$1.31	$1.37	$1.41	$0.37	$5.47	$3.88	$1.63	$2.87	$1.87	$17.58	$5.86	$5.57	$7.07	$1.69	$1.30	$1.11	$1.02	$1.23	$1.19	$1.18	$1.52
Shares Outstanding (M)	5,731M	5,686M	5,700M	5,709M	5,733M	5,708M	5,632M	5,675M	5,977M	1,212M	1,232M	1,251M	1,285M	6,895M	7,508M	7,870M	8,074M	7,045M	6,750M	6,939M	7,274M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PFE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$14.5B	$17.6B	$16.7B	$14.7B	$13.7B	$17.8B	$17.7B	$13.3B
Gross Profit	$9.7B	$12.3B	$12.5B	$9.4B	$9.8B	$13.0B	$10.8B	$8.2B
Gross Margin %	67.3%	70.0%	75.0%	64.3%	71.7%	73.0%	60.9%	62.1%
Operating Income (EBIT)	$4.0B	$3.7B	$3.5B	$3.6B	$4.6B	$5.7B	$5.0B	$1.9B
Operating Margin %	27.9%	21.0%	21.3%	24.4%	33.7%	32.2%	28.1%	14.1%
Net Income	$2.7B	($1.6B)	$3.5B	$2.9B	$3.0B	$403M	$4.5B	$24M
Net Margin %	18.6%	-9.4%	21.3%	19.9%	21.6%	2.3%	25.3%	0.2%
EBITDA	$5.0B	$756M	$5.6B	$5.3B	$5.1B	$5.1B	$7.3B	$2.4B
Earnings Per Share (EPS)	$0.47	$-0.29	$0.62	$0.51	$0.52	$0.07	$0.78	$0.00
Shares Outstanding (M)	5,731M	5,686M	5,714M	5,706M	5,710M	5,703M	5,705M	5,696M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PFE Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$12.0B	$11.7B	$12.7B	$8.7B	$29.3B	$32.6B	$14.4B	$12.6B	$15.8B	$16.5B	$15.9B	$14.5B	$16.9B	$17.8B	$17.1B	$20.2B	$11.5B	$16.6B	$18.2B	$13.4B	$17.6B
Capital Expenditures (CapEx)	$2.5B	$2.6B	$2.9B	$3.9B	$3.2B	$2.7B	$2.8B	$2.6B	$2.2B	$2.2B	$2.0B	$1.5B	$1.6B	$1.5B	$1.3B	$1.7B	$1.5B	$1.2B	$1.7B	$1.9B	$2.0B
Free Cash Flow (FCF)	$9.5B	$9.1B	$9.8B	$4.8B	$26.0B	$29.9B	$11.6B	$10.0B	$13.6B	$14.3B	$13.9B	$13.0B	$15.3B	$16.3B	$15.7B	$18.6B	$9.9B	$15.4B	$16.5B	$11.5B	$15.5B
FCF Margin %	15.0%	14.5%	15.5%	8.1%	25.9%	36.7%	27.9%	24.3%	25.4%	27.1%	26.3%	26.6%	30.8%	31.6%	28.8%	30.4%	14.8%	30.8%	34.2%	23.7%	32.1%
Dividends Paid	$9.8B	$9.8B	$9.5B	$9.2B	$9.0B	$8.7B	$8.4B	$8.0B	$8.0B	$7.7B	$7.3B	$6.9B	$6.6B	$6.6B	$6.5B	$6.2B	$6.1B	$5.5B	$8.5B	$8.0B	$6.9B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PFE Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$2.6B	$5.3B	$4.6B	($582M)	$2.3B	$6.7B	$6.7B	($1.8B)
Capital Expenditures (CapEx)	$436M	$845M	$602M	$618M	$564M	$917M	$651M	$637M
Free Cash Flow (FCF)	$2.2B	$4.5B	$4.0B	($1.2B)	$1.8B	$5.8B	$6.1B	($2.4B)
FCF Margin %	15.1%	25.7%	24.0%	-8.2%	12.9%	32.7%	34.2%	-18.2%
Dividends Paid	$2.4B	$2.4B	$2.4B	$2.4B	$2.4B	$2.4B	$2.4B	$2.4B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PFE Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$207.6B	$208.2B	$213.4B	$226.5B	$197.2B	$181.5B	$154.2B	$167.5B	$159.4B	$171.8B	$171.6B	$167.5B	$169.3B	$172.1B	$185.8B	$188.0B	$195.0B	$212.9B	$111.1B	$115.3B	$114.8B
Cash & Cash Equivalents	$1.7B	$1.1B	$1.0B	$2.9B	$416M	$1.9B	$1.8B	$1.3B	$1.1B	$1.3B	$2.6B	$3.6B	$3.3B	$2.2B	$10.1B	$3.2B	$1.7B	$2.0B	$2.1B	$3.4B	$1.8B
Total Liabilities	$117.2B	$121.4B	$124.9B	$137.2B	$101.3B	$104.0B	$90.8B	$104.0B	$95.7B	$100.1B	$111.8B	$102.5B	$97.7B	$95.5B	$104.1B	$105.4B	$106.7B	$122.5B	$53.4B	$50.1B	$44.1B
Total Debt (Short + Long-Term)	$63.7B	$64.3B	$64.0B	$71.4B	$35.8B	$38.4B	$39.8B	$52.1B	$41.7B	$43.5B	$42.1B	$39.0B	$36.7B	$36.5B	$37.5B	$38.9B	$44.0B	$48.7B	$17.3B	$13.1B	$8.0B
Total Shareholders' Equity	$90.1B	$86.5B	$88.2B	$89.3B	$95.9B	$77.5B	$63.5B	$63.4B	$63.8B	$71.7B	$59.8B	$65.0B	$71.6B	$76.3B	$81.3B	$82.2B	$87.8B	$90.0B	$57.6B	$65.0B	$71.4B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PFE viewer.

Other Companies in Pharmaceuticals

LLY · Lilly (Eli) — $1.07 trillion
JNJ · Johnson & Johnson — $635 billion
MRK · Merck & Co. — $324 billion
BMY · Bristol Myers Squibb — $127 billion
ZTS · Zoetis — $32 billion
VTRS · Viatris — $20 billion

← PFAI All stocks PFG →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.